The budget reconciliation bill, known as the One Big Beautiful Bill (OBBB), a broad spending and tax bill that includes significant healthcare policies, is now on its way to President Trump after ...

ASCO’s Leadership Development Program (LDP) prepares you to become a leader while giving you exclusive access to ASCO leaders and the broader oncology community, as well as a robust network of past ...

On June 20, 2025, the Centers for Medicare & Medicaid Services (CMS) released the 2025 Marketplace Integrity and Affordability final ruleaimed at addressing improper enrollments in the ACA Health ...

America’s Health Insurance Plans (AHIP)—a trade group representing the U.S. health insurance industry—announced a commitment from participating plansto improve prior authorization processes. The ...

Medicare Advantage Audits Are Expanding. What Do Oncology Practices Need to Know? Continuing its efforts to reduce fraud, waste, and abuse in Medicare, the Centers for Medicare & Medicaid Services ...

A new article in JCO Oncology Practice (JCO OP) looks at the root causes of cancer drug shortages in the United States (U.S.), the impact of these shortages on patients and providers, and makes ...

While federal prior authorization reform legislation has yet to make it over the finish line and be enacted into law, state governments continue to pass legislation to mitigate the burdensome ...

CHICAGO — Results from the international phase 3 AMPLITUDE clinical trial found that adding niraparib to abiraterone acetate (AKEEGA™) plus prednisone (AAP) can help slow cancer growth for people with ...

CHICAGO — Results from the phase 3 DESTINY-Breast09 clinical trial found that the combination of trastuzumab deruxtecan (Enhertu®) with pertuzumab (Perjeta®) can delay cancer growth for longer than ...

“The pace of therapeutic advances in upper gastrointestinal cancers has accelerated in recent years. Now, the MATTERHORN trial shows that perioperative treatment with FLOT plus durvalumab is better ...

“This is the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer to demonstrate that post-treatment exercise is both achievable and effective in improving ...

Switching to Camizestrant After Detection of an ESR1 Mutation Improves Progression-Free Survival for Some Patients With Advanced Breast Cancer ...